JP2006503905A - 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬 - Google Patents

炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬 Download PDF

Info

Publication number
JP2006503905A
JP2006503905A JP2005500317A JP2005500317A JP2006503905A JP 2006503905 A JP2006503905 A JP 2006503905A JP 2005500317 A JP2005500317 A JP 2005500317A JP 2005500317 A JP2005500317 A JP 2005500317A JP 2006503905 A JP2006503905 A JP 2006503905A
Authority
JP
Japan
Prior art keywords
ssri
composition
patient
peg
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005500317A
Other languages
English (en)
Japanese (ja)
Inventor
パラニヤンディ マニバサカム
ブレンダン スミス
ジェイソン フォン
ベンジャミン エイ． オースピッツ
エム． ジェイムズ ニコラス
カーティス キース
グラント アール． ツィマーマン
ブラッドリー ビー． ブラッシャー
ノア サッシュ
トッド ダブリュ． チャペル
エドワード ロイドン ジョスト−プライス
Original Assignee
コンビナトアールエックス インコーポレーティッド
パラニヤンディ マニバサカム
ブレンダン スミス
ジェイソン フォン
ベンジャミン エイ． オースピッツ
エム． ジェイムズ ニコラス
カーティス キース
グラント アール． ツィマーマン
ブラッドリー ビー． ブラッシャー
ノア サッシュ
トッド ダブリュ． チャペル
エドワード ロイドン ジョスト−プライス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006503905(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by コンビナトアールエックス インコーポレーティッド, パラニヤンディ マニバサカム, ブレンダン スミス, ジェイソン フォン, ベンジャミン エイ． オースピッツ, エム． ジェイムズ ニコラス, カーティス キース, グラント アール． ツィマーマン, ブラッドリー ビー． ブラッシャー, ノア サッシュ, トッド ダブリュ． チャペル, エドワード ロイドン ジョスト−プライス filed Critical コンビナトアールエックス インコーポレーティッド
Publication of JP2006503905A publication Critical patent/JP2006503905A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2005500317A 2002-09-24 2003-09-24 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬 Pending JP2006503905A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42752602P 2002-11-19 2002-11-19
US42742402P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (fr) 2002-09-24 2003-09-24 Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires

Publications (1)

Publication Number Publication Date
JP2006503905A true JP2006503905A (ja) 2006-02-02

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005500317A Pending JP2006503905A (ja) 2002-09-24 2003-09-24 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬

Country Status (12)

Country Link
EP (1) EP1553955A4 (fr)
JP (1) JP2006503905A (fr)
AR (1) AR041386A1 (fr)
AU (1) AU2003299196A1 (fr)
BR (1) BR0314713A (fr)
CA (1) CA2509526A1 (fr)
HR (1) HRP20050355A2 (fr)
IS (1) IS7811A (fr)
MX (1) MXPA05003152A (fr)
NO (1) NO20051669L (fr)
TW (1) TW200422042A (fr)
WO (1) WO2004030618A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006335714A (ja) * 2005-06-03 2006-12-14 Hisamitsu Pharmaceut Co Inc 経皮投与製剤
JP2010502736A (ja) * 2006-09-08 2010-01-28 オレ・ファーマシューティカルズ・インコーポレーテッド 消化管の炎症を低減または軽減するための方法
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004212919A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
CA2538023A1 (fr) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Schemas posologiques therapeutiques pour une administration de combinaisons de medicaments
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2585317C (fr) * 2004-11-19 2015-02-24 N.V. Organon Association de medicaments pour le traitement de depressions et de troubles s'y rapportant, comprenant un inhibiteur selectif de la recapture dela serotonine depression
EP1719507B1 (fr) * 2005-04-13 2010-07-14 Astion Development A/S Des agonistes de bêta-2 adrénocepteur pour le traitement de maladies des tissus conjonctifs de la peau
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2008033754A2 (fr) * 2006-09-11 2008-03-20 Duke University Méthodes et compositions de traitement de la dépression vasculaire.
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
PT117765A (pt) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa Formulação tópica de fluvoxamina para o tratamento de psoríase
WO2024074699A1 (fr) * 2022-10-07 2024-04-11 Oculis Operations Sarl Microsuspensions de gouttes oculaires d'inhibiteurs de mtor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500339A (ja) * 1991-10-15 1995-01-12 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
WO1998002169A2 (fr) * 1996-07-15 1998-01-22 Alza Corporation Nouvelles preparations pour l'administration de fluoxetine
JP2002504091A (ja) * 1997-03-18 2002-02-05 ベーアーエスエフ アクツィエンゲゼルシャフト コルチコステロイドに対する応答性を調整するための方法及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500339A (ja) * 1991-10-15 1995-01-12 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
WO1998002169A2 (fr) * 1996-07-15 1998-01-22 Alza Corporation Nouvelles preparations pour l'administration de fluoxetine
JP2002504091A (ja) * 1997-03-18 2002-02-05 ベーアーエスエフ アクツィエンゲゼルシャフト コルチコステロイドに対する応答性を調整するための方法及び組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009049972, Ｈｕｍａｎ Ｐｓｙｃｈｏｐｈａｒｍａｃｏｌｏｇｙ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ, 2001, Ｖｏｌ．１６, ｐ．９５−１０３ *
JPN6009049976, Ｐｓｙｃｈｉａｔｒｙ Ｒｅｓｅａｒｃｈ, 2000, Ｖｏｌ．９６, ｐ．２５５−２６６ *
JPN6009049979, Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｒｈｅｕｍａｔｏｌｏｇｙ, 1998, Ｖｏｌ．３７, ｐ．１０７７−１０８３ *
JPN6009049984, Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｉｍｍｕｎｏｌｏｇｙ, 1992, Ｖｏｌ．３９, ｐ．１０９−１２２ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006335714A (ja) * 2005-06-03 2006-12-14 Hisamitsu Pharmaceut Co Inc 経皮投与製剤
JP2010502736A (ja) * 2006-09-08 2010-01-28 オレ・ファーマシューティカルズ・インコーポレーテッド 消化管の炎症を低減または軽減するための方法
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤

Also Published As

Publication number Publication date
HRP20050355A2 (en) 2005-10-31
WO2004030618A2 (fr) 2004-04-15
MXPA05003152A (es) 2006-04-27
WO2004030618A3 (fr) 2005-04-07
BR0314713A (pt) 2005-07-26
EP1553955A4 (fr) 2008-11-05
AR041386A1 (es) 2005-05-18
NO20051669L (no) 2005-06-10
IS7811A (is) 2005-04-19
CA2509526A1 (fr) 2004-04-15
EP1553955A2 (fr) 2005-07-20
AU2003299196A1 (en) 2004-04-23
TW200422042A (en) 2004-11-01

Similar Documents

Publication Publication Date Title
JP2006517969A (ja) 免疫炎症性障害の治療のための組み合わせ療法
JP2007508391A (ja) 免疫炎症性障害の治療のための方法および試薬
US20100210606A1 (en) Methods and reagents for the treatment of inflammatory disorders
US20090075951A1 (en) Methods and Reagents for the Treatment of Inflammatory Disorders
WO2005079284A2 (fr) Methodes et reactifs pour le traitement de maladies et de troubles lies a des niveaux accrus de cytokines proinflammatoires
HRP20050355A2 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20060286177A1 (en) Methods and reagents for the treatment of inflammatory disorders
US20040220153A1 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
RU2329037C2 (ru) Комбинированная терапия для лечения иммуновоспалительных заболеваний
ZA200502708B (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MXPA06005457A (es) Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios
MXPA06005757A (en) Methods and reagents for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051207

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051209

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051209

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100315